data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
NeuroBo Pharmaceuticals
(NASDAQ:NRBO)
$0.4717
-0.0183[-3.73%]
At close: Jun 30
$0.56
0.0883[18.72%]
After Hours: 7:58PM EDT
Day High/Low0.46 - 0.49
52 Week High/Low0.37 - 5.63
Open / Close0.46 / 0.48
Float / Outstanding16.5M / 26.7M
Vol / Avg.60.5K / 127.2K
Mkt Cap12.6M
P/E-
50d Avg. Price0.52
Div / Yield-
Payout Ratio-
EPS-0.17
Total Float16.5M

NeuroBo Pharmaceuticals (NASDAQ:NRBO), Quotes and News Summary

NeuroBo Pharmaceuticals (NASDAQ: NRBO)

Day High/Low0.46 - 0.49
52 Week High/Low0.37 - 5.63
Open / Close0.46 / 0.48
Float / Outstanding16.5M / 26.7M
Vol / Avg.60.5K / 127.2K
Mkt Cap12.6M
P/E-
50d Avg. Price0.52
Div / Yield-
Payout Ratio-
EPS-0.17
Total Float16.5M
Sector: Health Care.Industry: Biotechnology
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-15
REV
Q1 2022Est.ActualSurprise
EPS-0.110
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

NeuroBo Pharmaceuticals Questions & Answers

Q
How do I buy NeuroBo Pharmaceuticals (NRBO) stock?
A

You can purchase shares of NeuroBo Pharmaceuticals (NASDAQ: NRBO) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are NeuroBo Pharmaceuticals's (NRBO) competitors?
Q
What is the target price for NeuroBo Pharmaceuticals (NRBO) stock?
A

The latest price target for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was reported by HC Wainwright & Co. on Monday, February 1, 2021. The analyst firm set a price target for 16.00 expecting NRBO to rise to within 12 months (a possible 3291.99% upside). 0 analyst firms have reported ratings in the last year.

Q
Current Stock Price for NeuroBo Pharmaceuticals (NRBO)?
A

The stock price for NeuroBo Pharmaceuticals (NASDAQ: NRBO) is $0.4717 last updated June 30, 2022, 8:00 PM UTC.

Q
Does NeuroBo Pharmaceuticals (NRBO) pay a dividend?
A

There are no upcoming dividends for NeuroBo Pharmaceuticals.

Q
When is NeuroBo Pharmaceuticals (NASDAQ:NRBO) reporting earnings?
A

NeuroBo Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 15, 2022.

Q
Is NeuroBo Pharmaceuticals (NRBO) going to split?
A

There is no upcoming split for NeuroBo Pharmaceuticals.

Q
What sector and industry does NeuroBo Pharmaceuticals (NRBO) operate in?
A

NeuroBo Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.